Carlsmed, Inc.

Carlsmed, Inc. is a commercial-stage medical technology company that designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company's primary product is aprevo, a comprehensive technology platform for spine fusion surgery procedures. The aprevo platform includes proprietary surgical planning software that uses outcomes-based algorithms aided by artificial intelligence. It also produces custom-built, anatomically designed vertebral interbody implants. By combining AI-driven planning with patient-specific implants, Carlsmed aims to improve surgical outcomes for individuals undergoing spine fusion surgery.

Carlsmed, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CARL. The company trades in United States Dollars (USD). As a Nasdaq-listed company, it is subject to the reporting and regulatory requirements of the U.S. Securities and Exchange Commission (SEC), providing transparency to investors.

Carlsmed, Inc. operates in the Healthcare sector, specifically within the Health Information Services industry. This classification reflects the company's focus on using technology and data analytics to improve healthcare delivery. While Carlsmed manufactures physical implants, its core value proposition lies in its AI-powered surgical planning software, which falls under health information services. The company's work sits at the intersection of medical devices and digital health, leveraging artificial intelligence to personalize spine surgery.

Carlsmed, Inc. is headquartered in Carlsbad, California, United States. The company was incorporated in 2018, making it a relatively young player in the medical technology space. Despite its recent founding, Carlsmed has already reached the commercial stage with its aprevo platform. The company serves the U.S. market, as indicated by its country and region designation. Its location in Southern California places it within a major hub for medical device innovation.

Carlsmed, Inc. generates revenue by selling its AI-enabled personalized spine surgery solutions. The company's aprevo platform combines proprietary surgical planning software with custom-built vertebral interbody implants. Surgeons use the software to plan spine fusion procedures, and Carlsmed manufactures patient-specific implants based on those plans. The company likely earns revenue from both the software (possibly through licensing or per-case fees) and the sale of the custom implants. As a commercial-stage company, Carlsmed focuses on gaining adoption among spine surgeons and hospitals, with the goal of establishing aprevo as a standard of care for spine fusion surgery.